Sermorelin: research, legal status and who sells it
Sermorelin is the shortest fully active analogue of growth hormone-releasing hormone. It was approved in the US as Geref, which is now discontinued.
By Editorial team. Updated Oct 14, 2026.
Awaiting expert review
This page is information, not medical advice. Sermorelin was once an approved prescription drug, but its approvals were withdrawn; research-grade versions sold online are not those products. We don't publish dosing or usage instructions.
- Also known as
- GRF (1-29), Geref, Sermorelin acetate
- Category
- Synthetic GHRH(1-29) analogue (formerly approved in the US)
- Evidence level
- Formerly approved drug (approvals withdrawn)
- Approved products
- Geref (discontinued) (US, 1990); Geref (discontinued) (US, 1997)
- Price range
- $2.10/mg to $18.18/mg, median $7.50/mg across 62 vendors (compare)
- Our lab tests
- None yet (how testing will work)
Legal and regulatory status
| Where | Status |
| United States | Approved by the FDA as Geref in 1990 and 1997; both products were discontinued in 2008, and FDA withdrew both approvals effective June 18, 2009 [1][2][13]. |
|---|
| United Kingdom | No UK-licensed medicine containing sermorelin appears in the MHRA products database [3]. |
|---|
| European Union | No medicine containing sermorelin is authorized in the EU, according to EMA's central and Article 57 product data [4][5]. |
|---|
| Canada | No product containing sermorelin appears in Health Canada's Drug Product Database [6]. |
|---|
| Australia | Schedule 4 (prescription-only) in Australia's Poisons Standard, which also lists growth hormone releasing hormones (GHRHs), including those named separately in Schedule 4, among poisons that must not be possessed without authority (Appendix D) [7]. |
|---|
| Sport (WADA) | Named as a prohibited growth hormone-releasing hormone analogue under S2 [8]. |
Summaries of official sources, checked Oct 14, 2026. Rules change; follow the source links. Not legal advice.
What it is
Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone (GHRH) and the shortest synthetic peptide with the full biological activity of GHRH [9]. It stimulates growth hormone secretion from the pituitary gland [9].
Research status
Sermorelin was used as a diagnostic test for growth hormone deficiency and, based on limited data, to treat some prepubertal children with idiopathic growth hormone deficiency [9]. A 1999 review found that it induced catch-up growth in most of these children and that its effect on final adult height had not been established; the recommended regimen had not been compared directly with somatropin, and growth gains with some other ways of giving sermorelin were smaller than with somatropin [9]. In adults, a 2020 review of growth hormone secretagogues, including sermorelin, in men with low testosterone found that clinical data were scarce [10]. A 2026 review in Sports Medicine listed sermorelin among peptides marketed directly to patients for musculoskeletal and performance uses [11].
Regulatory status
The FDA approved sermorelin as Geref in 1990 and 1997; both products were discontinued in 2008, and FDA withdrew both approvals effective June 18, 2009 [1][2][13]. No sermorelin medicine is authorized in the UK, the EU or Canada [3][4][6]. Australia lists sermorelin in Schedule 4 (prescription-only) and bars possession of growth hormone releasing hormones without authority (Appendix D) [7], and WADA names it as a prohibited growth hormone-releasing hormone analogue [8].
Quality and testing considerations
Because both Geref applications are discontinued, there is no currently marketed FDA-approved sermorelin product to compare against [1][2]. Black-market growth-promoting products analyzed by anti-doping laboratories have contained modified versions of known peptides, such as growth hormone-releasing peptides with an extra glycine [12], so identity should be confirmed by mass spectrometry rather than assumed from a label.
Where it’s sold
Sermorelin is sold online by research-chemical vendors; the tables below track current listings.
Sermorelin compared
Sermorelin prices: cheapest listings
The five lowest $/mg listings out of 90. See all Sermorelin prices
Prices come from each vendor's public product feed and were last fetched Oct 15, 2026.
They exclude shipping and discounts. $/mg uses the labeled amount, not measured content. A transparency score marked * is based on fewer than six checks; checks we couldn't complete score 0. How we compare prices.
Sources
- Drugs@FDA: NDA 019863 (Geref), original approval 28 December 1990, discontinued. U.S. Food and Drug Administration. Accessed Oct 14, 2026
- Drugs@FDA: NDA 020443 (Geref), original approval 26 September 1997, discontinued. U.S. Food and Drug Administration. Accessed Oct 14, 2026
- MHRA Products: licensed-medicine search for "sermorelin". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 14, 2026
- EMA medicines data: centrally authorised human medicines (export of 14 October 2026). European Medicines Agency. Accessed Oct 14, 2026
- EMA Article 57 product data: medicines authorised in the EU/EEA (data as of 9 October 2026). European Medicines Agency. Accessed Oct 14, 2026
- Drug Product Database online query (searched by active ingredient). Health Canada. Accessed Oct 14, 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327, registered 30 September 2026). Federal Register of Legislation, Australian Government. Accessed Oct 14, 2026
- World Anti-Doping Code International Standard: Prohibited List 2026 (in force 1 January 2026). World Anti-Doping Agency. Accessed Oct 14, 2026
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs (1999). Accessed Oct 14, 2026
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology (2020). Accessed Oct 14, 2026
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine (2026). Accessed Oct 14, 2026
- Analysis of new growth promoting black market products. Growth Hormone & IGF Research (2018). Accessed Oct 14, 2026
- Determination That GEREF (Sermorelin Acetate) Injection ... Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (78 FR 14095, March 4, 2013). U.S. Food and Drug Administration, Federal Register. Accessed Oct 15, 2026